ClinicalTrials.gg
Status unknownNCT03715114Updated Oct 22, 2018

A Study to Assess the Safety and Pharmacokinetics of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Subjects

A Phase 1 interventional study of GV-971 and Placebo in Pharmacokinetics and Safety, sponsored by Shanghai Greenvalley Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-22.

Sponsored by Shanghai Greenvalley Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

To evaluate the safety and pharmacokinetics of GV-971 capsules after oral a single or multiple doses of 900 mg, 1200 mg and 1500 mg in healthy subjects.

02

Conditions studied

  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

Shanghai Greenvalley Pharmaceutical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects;
  2. Age:≥18 and ≤40 on the date signing ;
  3. (BMI): 19-26 kg/m2 and the weight ≥50 kg for male and ≥45 kg for female;
  4. Subjects are able to understand the study procedures and methods, and willing to strictly comply with the protocol and give written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Subjects may be allergic to GV-971 in the opinion of the investigator;
  2. With diseases which could impact on the absorption, distribution, metabolism and excretion (ADME) of study drugs or protocol adherence in the opinion of the investigator (such medical disorder/disease may relate to cardiovascular, liver, kidney, digestive, immune, blood, endocrine, metabolic, cancer, neuropsychiatric,etc );
  3. Blood donation of ≥400 mL or severe blood lose and the volume of blood loss ≥400 mL within 12 weeks prior to screening;
  4. Participation in any drug or medical instrument study within 3 months prior to screening;
  5. Use of any prescription medicine or herbal remedy, over the counter medication or dietary supplements such as vitamin, calcium within 2 weeks prior to screening;
  6. Smoking more than 10 cigarettes a day, drugs or alcohol abuse within 6 months prior to screening;
  7. Use of heparin, alginic sodium diester , mannose ester within 4 weeks prior to screening;
  8. abnormalities in physical examination and laboratory test results or 12-lead , etc. in screening;
  9. Clinically significant abnormalities in Chest X-ray or abdominal B-ultrasound examination;
  10. Positive seurology screen for ( HBsAg), (HCV), and USR unheated serum reagin test;
  11. Vegetarian or person with dietary restrictions;
  12. Subjects able to father a child are unwilling to use highly effective physical form of from the trial period until 3 months after the completion of study;
  13. Any other reasons that the subject is not eligible for participation in the study in the opinion of the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    GV-971 900 mg

    900 mg oral

    Drug: GV-971

  • Experimental
    GV-971 1200 mg

    1200 mg oral

    Drug: GV-971

  • Experimental
    GV-971 1500 mg

    1500 mg oral

    Drug: GV-971

  • Placebo comparator
    Placebo

    Oral placebo

    Drug: Placebo

Interventions

  • DrugGV-971

    Oral GV-971

    Also known as: Sodium Oligo-mannurarate

  • DrugPlacebo

    Oral Placebo

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax)

    Cmax will be determined after oral 900 mg, 1200 mg and 1500 mg of GV-971

    Time frame: 2 day and 7 day

  2. Half life time (T1/2)

    T1/2 will be determined after oral 900 mg, 1200 mg and 1500 mg of GV-971

    Time frame: 2 day and 7 day

  3. Area under the plasma concentration versus time curve (AUC)

    AUC will be determined after oral 900 mg, 1200 mg and 1500 mg of GV-971

    Time frame: 2 day and 7 day

  4. Time to the peak drug concentration (Tmax)

    Tmax will be determined after oral 900 mg, 1200 mg and 1500 mg of GV-971

    Time frame: 2 day and 7 day

Secondary outcomes

  1. Adverse Event (AE)

    AE occurred after oral 900 mg, 1200 mg and 1500 mg of GV-971

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • Phase-I Clinical Research Unit at Shanghai Xuhui Center hospital
    Shanghai, Shanghai 200031, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2018 (actual). Primary completion is estimated for Nov 2018, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2018
First posted
Oct 22, 2018
StartActual
Oct 15, 2018
Primary completionEst.
Nov 30, 2018
CompletionEst.
Dec 31, 2018
Last update
Oct 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03715114
Lead sponsor
Shanghai Greenvalley Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 22, 2018
Start date
Oct 15, 2018
Primary completion
Nov 30, 2018 (estimated)
Completion
Dec 31, 2018 (estimated)
Last update
Oct 22, 2018

Study contacts

Xianliang Xin, Ph D
Contact
xinxianliang@gv-ri.com
+86-21-50504988 ext. 1097
Chen Yu, MD
principal investigator · Shanghai Xuhui Center hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GV-971

Start the discussion